![Thomas Zindrick](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Zindrick
Chief Executive Officer at
GENELUX CORPORATION
Net worth: 2 M $ as of 2026-05-30
Profile
Thomas D.
Zindrick is Chairman, President & Chief Executive Officer at Genelux Corp.
since 2023 and Executive Vice Chairman at Aeromics, Inc. since 2018.
Former roles include Director at DNX Biopharmaceuticals, Inc. from 2014 to 2020, Director at Amitech Therapeutic Solutions, Inc. from 2014 to 2021, Attorney at The Dow Chemical Co., and Vice President & Associate General Counsel at Amgen, Inc. from 2008 to 2009.
Education includes undergraduate studies at North Central College and graduate studies at the University of Illinois College of Law.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GENELUX CORP. 1.19% | 2026-05-10 | 532,051 ( 1.19% ) | 2 M $ | 2026-05-30 |
Thomas Zindrick active positions
| Companies | Position | Start |
|---|---|---|
| GENELUX CORPORATION | Chief Executive Officer | 2014-05-27 |
Aeromics, Inc.
 Aeromics, Inc. BiotechnologyHealth Technology Operates preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke | Director/Board Member | 2018-08-15 |
Former positions of Thomas Zindrick
| Companies | Position | End |
|---|---|---|
Amitech Therapeutic Solutions, Inc | Chief Executive Officer | 2021-01-31 |
DNX Biopharmaceuticals, Inc.
 DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic proteins for the treatment of patients with life-long diseases | Director/Board Member | 2020-02-29 |
| AMGEN INC. | Compliance Officer | 2007-12-31 |
| DOW CHEMICAL COMPANY (THE) | Corporate Officer/Principal | - |
Training of Thomas Zindrick
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
92
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
The Dow Chemical Co.
 The Dow Chemical Co. Chemicals: Major DiversifiedProcess Industries Manufactures specialty additives, modifiers and plastic polyethylene products | Process Industries |
Genelux Corp.
 Genelux Corp. Pharmaceuticals: MajorHealth Technology Manufactures and markets drugs and virus strains solutions | Health Technology |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Operates preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke | Health Technology |
North Central College
 North Central College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois College of Law
 University of Illinois College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DNX Biopharmaceuticals, Inc.
DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic proteins for the treatment of patients with life-long diseases | Commercial Services |
Amitech Therapeutic Solutions, Inc |
- Stock Market
- Insiders
- Thomas Zindrick
